Wednesday, July 8, 2026

pharma · Influenza · Celiac Disease · BRNS

Barinthus Biotherapeutics

Barinthus Biotherapeutics is a pharma organization headquartered in Harwell, GB. It trades on NYSE under ticker BRNS. Primary therapeutic focus areas include Influenza, Celiac Disease, Chronic Hepatitis B, Hepatitis B, H

Harwell, GB HQ
2016 Founded
36 Employees
Public company Type
BRNS · NYSE Ticker
Company details
Status
Public
HQ
Harwell, GB
Founded
2016
Employees
36
Programs
9
Drugs
5
Patents
0
Clinical program

VTP-1000

Phase 1 · mab · Celiac Disease

VTP-1000 for Celiac Disease is a Phase 1 program (mab) at Barinthus Biotherapeutics plc. with 1 ClinicalTrials.gov record(s).

Internal code GLU001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Barinthus Biotherapeutics plc.
Phase
Phase 1
Modality
mab
Indication
Celiac Disease
Status
active
Trials
1

Clinical trials